Profile
Nanology Labs, a University of Toronto spin-off company, has developed a novel drug delivery platform technology with BBB-crossing capability. The company's lead therapeutic asset is a first-in-class nanomedicine that can turn cold tumors hot, reverse treatment-resistance in tumors and improve therapeutic outcome of radiation, chemo and immunotherapies.
Website
www.nanologylabs.comContact
-
Dr. Mohammad Ali Amini, President and Chief Executive OfficerTel: +1 647 447-7449Email: ma.amini@nanologylabs.com
Event details
Date: September 13 - 15, 2021
Event contact
Patricia Cosgrove
Area Director
USA: Life Sciences
Tel: +1 647-293-6306
Email: patricia.cosgrove@ontario.ca
Participants
6 in total
-
Artenga’s microbubble drug conjugates (MDC) and focused ultrasound (FUS) are key… -
KA Imaging has created color x-ray, which allows for early and more accurate diagnostics with higher radiology… -
Mediphage Bioceuticals, a preclinical-stage biotechnology company, is developing a next-generation non-viral gene… -
Nanology Labs, a University of Toronto spin-off company, has developed a novel drug delivery platform technology…
-
Nucro-Technics is a full-service Contract Support Organization that specializes in the conduct of both GLP… -
PocketMD is a 24/7 healthcare marketplace that connects patients with doctors and allied health professionals…